{
    "clinical_study": {
        "@rank": "166653", 
        "arm_group": [
            {
                "arm_group_label": "Alirocumab", 
                "arm_group_type": "Experimental", 
                "description": "Injection through subcutaneous administration With stable daily statin With or without other lipid modifying therapy - Type: Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Injection through subcutaneous administration With stable daily statin With or without other lipid modifying therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as\n      add-on therapy to stable daily statin therapy with or without other lipid modifying therapy\n      in comparison with placebo after 24 weeks of treatment in heterozygous familial\n      hypercholesterolemia or high cardiovascular risk patients with hypercholesterolemia.\n\n      Secondary Objectives:\n\n        -  To evaluate the long-term effect of alirocumab in comparison with placebo on LDL-C\n           after 52 weeks of treatment.\n\n        -  To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks\n           of treatment.\n\n        -  To evaluate the effect of alirocumab on other lipid parameters.\n\n        -  To evaluate the safety and tolerability of alirocumab.\n\n        -  To evaluate the development of anti-alirocumab antibodies.\n\n        -  To evaluate the PK of alirocumab."
        }, 
        "brief_title": "Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Hyperlipoproteinemia Type II"
            ]
        }, 
        "detailed_description": {
            "textblock": "Approximately 63 weeks (i.e., 14 months) (screening: 3 weeks, double-blind treatment period:\n      52 weeks, and follow-up period: 8 weeks)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Patients with heterozygous familial hypercholesterolemia or non-familial\n        hypercholesterolemia who are not adequately controlled with a stable daily dose of statin\n        with or without other lipid modifying therapy, at stable dose prior to the screening visit\n        (Week -3).\n\n        Exclusion criteria:\n\n          1. LDL-C <100 mg/dL (<2.59 mmol/L) at the screening visit (Week -3) in patients with\n             heterozygous familial hypercholesterolemia or in patients with non-familial\n             hypercholesterolemia who have a history of documented coronary heart disease as\n             described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of\n             Atherosclerotic Cardiovascular Diseases 2012.\n\n          2. LDL-C <120 mg/dL (<3.10 mmol/L) at the screening visit (Week -3) in patients with\n             non-familial hypercholesterolemia who have a history of documented diseases or other\n             risk factors as categorized in primary prevention category III as described in JAS\n             Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.\n\n          3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4\n             weeks prior to the screening visit (Week -3) or between screening and randomization\n             visits.\n\n          4. Age <20 years at the screening visit (Week -3).\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107898", 
            "org_study_id": "EFC13672", 
            "secondary_id": "U1111-1115-7486"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Pharmaceutical form:solution for injection Route of administration: subcutaneous", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Alirocumab", 
                "description": "Pharmaceutical form:solution for injection Route of administration: subcutaneous", 
                "intervention_name": "alirocumab SAR236553 (REGN727)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "pravastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "simvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "fluvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "pitavastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Alirocumab", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simvastatin", 
                "Atorvastatin", 
                "Fluvastatin", 
                "Pravastatin", 
                "Rosuvastatin", 
                "Pitavastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Adachi-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392029"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adachi-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392016"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aki-Gun", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392024"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392013"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392012"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukui-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392032"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaga-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392028"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanazawa-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawanishi-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392023"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kisarazu-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392009"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuki-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392011"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392017"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mito-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392007"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moriya-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392018"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oota-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392014"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392019"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392020"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392030"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392022"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oyabe-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392027"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392015"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392021"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takamatsu-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392025"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Alirocumab in Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percent change in calculated LDL-C", 
            "safety_issue": "No", 
            "time_frame": "From baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107898"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The percent change in calculated LDL-C", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 52"
            }, 
            {
                "measure": "The percent change in calculated LDL-C", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 12"
            }, 
            {
                "measure": "The proportion of patients reaching LDL-C goal", 
                "safety_issue": "No", 
                "time_frame": "At Week 24"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}